Mizuho raised the firm’s price target on Quest Diagnostics to $155 from $150 and keeps a Buy rating on the shares. The analyst increased estimates following the “solid” Q1 results. The main takeaway from the results was that base business trends remain strong, benefiting from broad-based elevated utilization as well as share gain in the physician and hospital markets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Notable companies reporting before tomorrow’s open
- Quest Diagnostics launches blood biomarker test for Alzheimer’s diagnosis
- Quest Diagnostics price target raised to $138 from $135 at Baird
- Quest Diagnostics and Broad Clinical Labs announce collaboration